Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Keros Therapeutics filed an 8-K on 9/8/25, check for updates.
AI Summary
On September 8, 2025, Keros Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates Keros Therapeutics is providing updates or submitting required documentation to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events, making the immediate risk level low.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Keros Therapeutics?
The filing is designated for 'Other Events' and 'Financial Statements and Exhibits', indicating it's for updates or required submissions rather than a specific material event announcement.
When was the earliest event reported in this filing?
The earliest event reported was on September 8, 2025.
What is Keros Therapeutics' principal executive office address?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics?
The SEC file number for Keros Therapeutics is 001-39264.
What is the fiscal year end for Keros Therapeutics?
Keros Therapeutics' fiscal year ends on December 31.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-08 08:02:13
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20250908.htm (8-K) — 37KB
- exhibit9919825pr.htm (EX-99.1) — 15KB
- 0001664710-25-000081.txt ( ) — 216KB
- kros-20250908.xsd (EX-101.SCH) — 2KB
- kros-20250908_def.xml (EX-101.DEF) — 17KB
- kros-20250908_lab.xml (EX-101.LAB) — 28KB
- kros-20250908_pre.xml (EX-101.PRE) — 17KB
- kros-20250908_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 8, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 8, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: September 8, 2025